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ABSTRACT
Introduction: While a number of strategies are being
implemented to control cardiovascular diseases (CVDs)
and type 2 diabetes mellitus (T2DM), the cost-
effectiveness of these in the South Asian context has
not been systematically evaluated. We aim to
systematically review the economic (cost-effectiveness)
evidence available on the individual-, group- and
population-level interventions for control of CVD and
T2DM in South Asia.
Methods and analysis: This review will consider all
relevant economic evaluations, either conducted
alongside randomised controlled trials or based on
decision modelling estimates. These studies must
include participants at risk of developing CVD/T2DM or
with established disease in one or more of the South
Asian countries (India, Bangladesh, Pakistan, Sri Lanka,
Nepal, Maldives, Bhutan and Afghanistan). We will
identify relevant papers by systematically searching all
major databases and registries. Selected articles will be
screened by two independent researchers.
Methodological quality of the studies will be assessed
using a modified Drummond and a Phillips checklist.
Cochrane guidelines will be followed for bias
assessment in the effectiveness studies.
Results: Results will be presented in line with the
PRISMA (Preferred Reporting Items for Systematic
review and Meta-analysis) checklist, and overall quality
of evidence will be presented as per the GRADE (Grades
of Recommendation, Assessment, Development and
Evaluation) approach.
Ethics and dissemination: The study has received
ethics approval from the All India Institute of Medical
Sciences, New Delhi, India. The results of this review
will provide policy-relevant recommendations for the
uptake of cost-effectiveness evidence in prioritising
decisions on essential chronic disease care packages
for South Asia.
Study registration number: PROSPERO
CRD42013006479.
INTRODUCTION
Cardiovascular disease (CVD) and type 2 dia-
betes mellitus (T2DM) together contribute to
the largest burden of morbidity (14% of
disability-adjusted life years) and mortality (over
30% of all deaths) in South Asia.1 2 T2DM
doubles the risk of developing CVD, and
approximately half of patients with T2DM are
known to be hypertensive.3 4 By 2030, it is pro-
jected that there will be 120.9 million people
with diabetes in South Asia (90–95% of these
will have T2DM), more than double the
number affected in North America or Europe.2
South Asians experience higher case fatality
rates and rates of premature death due to CVD
(deaths occurring at least 10–15 years
younger) than the rest of the Western world.5 6
A report in 2010 suggested that the total
annual income loss to households affected by
CVDs in India was 144–158 billion INR.7 The
WHO estimates that India will lose US$237
billion due to heart disease, stroke and dia-
betes, which will slow the growth in India’s
GDP (gross domestic product) by 1% over the
next 10 years,8 thereby contributing to poverty.
The mortality and morbidity due to CVD/
T2DM thus impose a huge economic burden
on individuals, families and society, the health
system, and the economy as a whole.9 10
CVD and T2DM share various common
risk factors (unhealthy diet, physical inactiv-
ity, tobacco use, high blood pressure, dyslipi-
daemia and stress), and hence there is
considerable overlap in strategies used to
control these diseases.4
While the efﬁcacy and safety of various
interventions have been tested by several ran-
domised controlled clinical trials and subse-
quent systematic reviews and meta-analyses,
little is known about the cost-effectiveness of
these interventions from the perspective of
either the patient or the healthcare system.
Rationale: why is a systematic
review needed?
Scarcity of resources in South Asia
(Afghanistan, Bhutan, Bangladesh, India,
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Maldives, Nepal, Pakistan and Sri Lanka) has meant that
policy-makers have to make active decisions about
funding of interventions prioritised for inclusion in
essential care packages to maximise beneﬁt from the
limited resources.11 Promoting effective care without
considering the costs of care and the value of the health
gain leads to inefﬁcient use of public and private funds
allocated for healthcare, indirectly resulting in harm to
individuals and society rather than the intended good.12
Therefore, it is prudent to interpret treatment guide-
lines based on the safety and efﬁcacy measures com-
bined with the cost-effectiveness to help make decisions
more patient-oriented. The recent emerging trends of
prevention initiatives and national programmes to
control CVD and T2DM in the South Asian region
necessitate a renewed focus on economic aspects of
interventions. The current review will ﬁll this gap by sys-
tematically evaluating the cost-effectiveness of
interventions in South Asia. Results from this review will
enable policy-makers, clinicians and patient’s advocacy
groups in the resource-constrained South Asian setting
to make better ‘evidence-informed decisions’.
Aim
To systematically review the economic (cost-
effectiveness) evidence available on the individual-,
group- and population-level interventions used for
control of CVD and T2DM in South Asia.
Specific objectives
1. To summarise the cost-effectiveness evidence for
interventions to control CVD and T2DM in South
Asia.
2. To describe the quality of the economic evaluation
studies considering the key methodological issues
(time horizon, analytical viewpoint, outcome
measures).
3. To summarise the types of incremental resource
inputs, consequences and costs of implementing the
intervention, versus comparators.
METHODS AND ANALYSIS
Criteria for inclusion of studies in this review
Type of studies
We will include full economic evaluation studies (ie,
cost-effectiveness analyses, cost–utility analyses, cost–
beneﬁt analyses) based on either randomised controlled
trials or decision modelling-based cost-effectiveness
studies. This approach is more inclusive and we recog-
nise that different types of economic evaluations may
involve heterogeneity; therefore, we will classify and
analyse them separately in order to retain comparability
among a particular type of economic evaluation.
Type of participants
Studies that include individuals at risk (as deﬁned by the
study authors) of developing T2DM or CVD and/or
with established CVD or T2DM receiving treatment will
be included. Also, the economic evaluations must
include participants in one or more of the South Asian
countries: India, Bangladesh, Pakistan, Sri Lanka, Nepal,
Maldives, Bhutan and Afghanistan.
Types of interventions
We reviewed the current national health policy docu-
ments of South Asian countries to understand and
compile a list of strategies or interventions currently
being recommended to control CVD and T2DM in the
region. Table 1 summarises the results of this exercise.
In addition, clinical guidelines for T2DM and CVD man-
agement will be screened to identify the individual-,
group- and population-level interventions proposed in
table 2.
It will be of great value to summarise the evidence on
cost-effectiveness as the ﬁrst step in promoting the cost-
effective strategies for prevention and control of CVD
and T2DM. This will help make healthcare decisions
more accountable.
Types of outcome measures
We will report outcome measures as summarised in
table 3, if available in the published articles. If relevant
information is lacking, attempts will be made to obtain
maximum data on these outcome measures by contact-
ing primary authors.
Exclusion criteria
1. Non-economic evaluation studies.
2. Reviews, letters, abstracts, methodological and
general commentary or perspectives.
3. Economic evaluations reported for non-South Asian
countries.
4. Studies without English language titles and abstracts.
Locating studies and search strategy
The search for relevant studies will be carried out by two
independent reviewers. We will search the following elec-
tronic databases: (1) The Cochrane Library; (2) The
Database of Abstracts of Reviews of Effectiveness
(DARE)—contained in the Cochrane library search; (3)
Medline (1966+); (4) EMBASE (1980+), (5) National
Health Service Economic Evaluation Database (NHS
EED); (6) Health EED (HEED); (7) Centre for Reviews
and Dissemination (CRD) electronic database; (8) The
CEA Registry; (9) Econlit; (10) CINAHL; (11) Biomed
central; (12) PsychInfo; (13) Science Direct; (14) Web
of Science.
Relevant publications of the DCP2 (Disease Control
Priority 2) project and WHO-CHOICE programme will
be completely hand-searched for relevant articles. As the
use of technical terms for indexing international litera-
ture in databases is often inconsistent or errant, we will
deﬁne a search strategy with high sensitivity. The search
strategy will consist of freetext and MeSH terms related
to economic evaluation and CVD or T2DM. Further, the
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Table 1 Strategies or interventions recommended for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) in the national policy documents
No Countries Health policy documents (source) Recommended interventions/strategies
1. Afghanistan National Strategy for Prevention and Control of Non-communicable
diseases (NCDs), 2013–2018;13 endorsed by Ministry of Public Health
Afghanistan, General Directorate of Preventive Medicine NCD Prevention
and Control Department
(1) Introduce interventions targeted to reduce tobacco use, unhealthy diet,
physical inactivity, and harmful use of alcohol; (2) strengthen health
system and integrate NCD programme in PHC; (3) develop and
implement effective NCD advocacy plan; (4) health promotion, media
campaigns, workplace-based programmes, and promote
population-based interventions; (5) build capacity of healthcare workers;
(6) establish national diabetes registry and surveillance of NCD risk
factors (STEPS survey); (7) establish multisectoral partnerships
2. Bhutan National Policy and Strategic Frame-Work on Prevention and Control of
NCDs14 (Endorsed by the Royal Government of Bhutan 2009)
(1) Introduce alcohol and tobacco taxes; (2) introduce interventions to
improve physical activity in schools and community; (3) promote healthy
lifestyle initiatives; (4) strengthen health services to provide timely
treatment and continuum of care
3. Bangladesh Strategic Plan for Surveillance and Prevention of NCDs in Bangladesh,
2007–201015 (endorsed by Ministry of Health and Family Welfare)
(1) Health facility strengthening; (2) capacity building; (3) availability of
essential drugs; (4) screening of high-risk individuals; (5) development of
surveillance system
4. India National Programme for Prevention and Control of Cancer, Diabetes,
CVDs and Stroke (NPCDCS), 201016
(1) Prevention through behaviour change: mass media, community
education, and interpersonal communication to be used for increased
intake of healthy food, increased physical activity, avoidance of tobacco
and alcohol, and stress management; (2) opportunistic screening of those
individuals at high risk of developing T2DM and CVD; (3) range of
treatment services: health promotion, psychosocial counselling,
management (out- and in-patient), day care services, home-based care
and palliative care, and referral to specialised services
5. Maldives National Strategic Plan for Prevention and Control of NCDs 2008–201017 (1) Encourage healthy lifestyles in school and community setting—for
example, tobacco-free islands; (2) awareness campaigns and health
education session; (3) develop and disseminate treatment guidelines for
major NCDs; (4) conduct screening in high-risk groups; (5) integrate and
strengthen NCD management in PHC; (6) build capacity for care
providers
6. Nepal Integrated NCD Prevention and Control Policy of Nepal, 2007–0818 (1) Reduce tobacco use and alcohol consumption: ‘sin tax’; (2) establish
NCD surveillance system; (3) build capacity for healthcare workers; (4)
prioritise low-cost, cost-effective socio-culturally acceptable measures in
planning and implementation of NCD prevention and control
7. Pakistan National Action Plan for NCDs Pakistan, 200419 CVD and T2DM action plan: (1) integrate surveillance of CVD risk factors
with population-based NCD surveillance system; (2) promote physical
activity and healthy diet; (3) agricultural and fiscal policies to increase
access to healthy food; (4) population-level screening of risk factors; (5)
ensure availability of aspirin, β-blockers, thiazides, ACE inhibitors, statins
and penicillin at all levels of healthcare; (6) ensure availability of
antidiabetic agents (insulin, sulfonylureas, metformin) at all levels of
healthcare; (7) build capacity of health systems in support of CVD
prevention and control
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resulting hits will be ﬁltered for the occurrence of the
term ‘South Asian countries’. The search will include all
years up to 2014. Further the reference lists of identiﬁed
relevant studies and reviews will be hand-searched.
Keywords that will be used for building the search
strategy include:
▸ CVD OR T2DM: (heart disease, ischaemic heart disease,
myocardial infarction, congestive heart failure, hyper-
tension, cardiac disease, revascularisation, cardiac
rehabilitation, diabetes, DM, T2DM, impaired fasting
glucose, impaired glucose tolerance, pre-diabetes) AND
▸ Cost-effectiveness: (Costs OR (Cost analysis or cost-
analyses) OR (Cost-effective) OR (Cost-beneﬁt) OR
(Cost-utility) OR (Cost-minimisation) OR (Health
expenditure) OR (Cost estimate)) AND
▸ South Asian countries: (Afghanistan OR Bangladesh
OR Bhutan OR India OR Maldives OR Nepal OR
Pakistan OR Sri Lanka)
Data collection
Screening of studies for eligibility
We will import search results into Zotero and remove
duplicates as a ﬁrst step. Screening will then be con-
ducted in two phases. First, titles and abstracts will be
screened by one researcher to identify publications that
deﬁnitely do not meet the inclusion criteria. In doubtful
cases, the publication will be included. Second, the full
text of the selected publications will be screened by two
independent researchers to match the eligibility criteria.
Any disagreements will be resolved by consensus discus-
sion within the study team. The inter-rater reliability for
inclusion of economic studies will be calculated and
reported using κ statistics. Tables of excluded studies will
be prepared, detailing when exclusion occurred and the
reasons for exclusion. A predeﬁned data extraction form
will be used for this task. The form will be developed
and piloted on ﬁve economic studies to reﬁne it before
being used on all studies. Records of all studies will be
kept as per the PRISMA (Preferred Reporting Items for
Systematic review and Meta-analysis) checklist.21
Collecting data
We will collect information on characteristics of included
studies and their results. To describe the characteristics
of included studies, we will extract: year of study; details
of interventions and comparators; study design and
source(s) of resource use, unit costs and (if applicable)
effectiveness data; decision-making jurisdiction, geo-
graphical and organisational setting; analytical view-
point; and time horizon for both costs and effects.
Where information is missing, we will contact study
authors to request additional details.
For outcome measures, estimates of speciﬁc items of
resource use associated with interventions and compara-
tors, along with their unit costs, will be extracted in natural
units (eg, length of hospital stay in days, duration of oper-
ation in minutes, number of outpatient attendances, etc).
We will also collect information on the price year and
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Table 2 Interventions to be evaluated in this review (not exhaustive)
Pharmacological interventions
Surgical and percutaneous
interventions
Blood pressure-lowering
drugs Antiplatelet inhibitors Lipid-lowering drugs
Oral hypoglycaemic
agents Procedures
Individual-based interventions
ACE inhibitors Aspirin Atorvastatin Metformin Coronary artery bypass graft (CABG)
Angiotensin receptor
blocker
Clopidogrel Simvastatin Sulfonylureas Angioplasty
Calcium channel blockers Fibrates Insulin Cardiac rehabilitation
β-Blockers Cardiac resynchronisation therapy
(CRT)
Diuretics Implantable cardioverter-defibrillator
(ICD)
Polypill (fixed dose
combination cardiovascular
polypill)
Procedures to treat complications of
diabetes: amputation, laser
photocoagulation therapy etc.
Group/population-based interventions
Health education Health financingMultisectoral
approach (eg, agricultural policy)
Sin tax
High-risk screeningOpportunistic
screeningGeneral/whole population
screening
Peer-support
interventions
Lifestyle behavioural counselling
targeted at individual or
population-based strategy:
▸ Physical activity
▸ Diet
▸ Tobacco cessation
▸ Alcohol consumption
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currency used to calculate incremental cost estimates. Both
a point estimate and a measure of uncertainty (eg, SE or
CI) will also be extracted for measures of incremental
resource use, costs and cost-effectiveness, if reported. In
addition, details of any sensitivity analyses undertaken will
be collected.
Assessment of study quality
We will assess whether the published studies have
described economic analyses methods, assumptions,
models and possible biases in a way that is transparent, so
that the strength of economic studies can be determined.
Since the reliability of an economic evaluation is predi-
cated on its use of reliable effectiveness data, part of the
critical appraisal will involve considering sources of poten-
tial bias that apply to the randomised controlled trial.
In this review, the critical appraisal will therefore
consist of the following three elements:
1. Assessment of the risk of bias in results of the effect-
iveness studies (randomised controlled trial), using
Cochrane guidelines.
2. Assessment of the methodological quality of the eco-
nomic evaluations, using a modiﬁed Drummond
checklist22 and Evers checklist.23
3. Assessment of the methodological quality of decision
modelling studies, using Phillips checklist 2004.24
In general, factors that will be assessed for methodo-
logical quality are those related to applicability of ﬁnd-
ings, validity of individual studies, and certain design
characteristics that affect interpretation of results, such
as double blinding and adherence.25 26 Further, four
sources of bias will be checked in primary effectiveness
studies: selection bias, performance bias, attrition bias
and detection bias. Two reviewers will independently
assess the methodological quality of selected studies. It is
plausible that use of different data sources for measures
of resource use, cost and/or cost-effectiveness will
impact on results; therefore, sensitivity analysis will be
performed to assess how the outcomes measures are
inﬂuenced by adding some of the excluded economic
studies that did not meet the minimum quality require-
ments of a good-quality economic evaluation.
Analysing, interpreting and reporting results
Presenting results in tables and narrative summary
We will use appropriate analytical methods for summar-
ising the results of this review. If applicable, a
meta-analysis of resource use or cost data, or develop-
ment of an economic model, may be considered. In
addition to reporting the characteristics of included
studies, a summary table of various checklists completed
to inform assessments of the methodological quality of
economic evaluations will be presented. Also, we will
report a commentary on the main characteristics and
results of included studies (measures of incremental
resource use, cost and cost-effectiveness).
Costs will be presented in real currency (as of the year
of study or adjusted to current year) as this will be
relevant for the readers in the countries under study.
In addition, in order to facilitate comparison of cost esti-
mates collected from different studies, an international
exchange rate based on purchasing power parities
(PPPs) will be used to convert cost estimates into a
target currency—that is, international dollars—and GDP
deﬂators will be used to convert cost estimates into a
ﬁxed price year.
Addressing reporting and publication biases
Publication bias will be detected by a funnel plot, if
there are more than 10 studies in a particular interven-
tion category. If asymmetry is seen, this will be discussed
to consider reasons other than publication bias—for
example, selection bias, reporting bias, data irregular-
ities, true heterogeneity and artefacts. Subgroup analysis
will be performed to determine whether beneﬁt varies
across intervention types or countries.
Since English is the dominant language for health
research in South Asia, exclusion of non-English lan-
guage studies will introduce small bias.
Heterogeneity and sensitivity analyses
We will test heterogeneity of intervention effects among
trials using the standard χ2 statistic (p value) or the I2
statistic. We will consider a p value of >0.10 to be statistic-
ally signiﬁcant heterogeneity. Interpretation of I2 for
Table 3 Outcome measures to be reported in this review
Resource use Costs Cost-effectiveness
No of outpatient
attendances
Direct medical costs Incremental cost-effectiveness ratios
No of inpatient
hospitalisations
Indirect medical costs Cost per life years gained
Length of hospital stay
in days
Out-of-pocket expenses paid by
the participants/patients
Cost per QALYs (quality-adjusted life years) gained
Other direct medical
resource use
Costs of materials and
intervention delivery (training
cost)
Cost per DALYs (disability-adjusted life years) averted
Other indirect medical
resource use
Cost per unit reduction in risk factors (such as blood pressure,
blood sugar, HbA1c, low-density lipoprotein cholesterol)
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heterogeneity is as follows: 0–40%, may not be import-
ant; 30–60%, represents moderate heterogeneity; 50–
90%, represents substantial heterogeneity; 75–100%,
represents considerable heterogeneity.27 We will explore
the possible cause(s) of heterogeneity by conducting
various sensitivity analyses.
Summary of findings
Results of this review will be reported in line with the
PRISMA 2009 checklist.28 The overall quality of evidence
on outcomes will be presented using the GRADE
(Grades of Recommendation, Assessment, Development
and Evaluation) approach,29 which involves consider-
ation of within-study risk of bias (methodological
quality), directness of evidence, heterogeneity, precision
of effect estimates and risk of publication bias. We will
rate overall quality of evidence at four levels: high, mod-
erate, low and very low.
Ethics and dissemination
The systematic review protocol has been approved by
the institutional ethics committee of the All India
Institute of Medical Sciences, New Delhi, India. As such,
there are no ethical issues involved in this study, as it is
only a review of published economic evaluations and no
patient data will be collected.
Findings from this review will be submitted for publica-
tion in peer-reviewed journals. They will be shared with
decision-makers and health professionals as brief policy
notes. The study investigators will also disseminate ﬁnd-
ings through professional conferences, targeting primary
and secondary care physicians, health economists, and
public health policy-makers more widely. While there has
been an increasing interest in South Asian countries to
scale-up the most cost-effective individual-, group- and
population-level interventions for CVD and T2DM man-
agement, major research gaps will be identiﬁed through
this review. The results of this study will provide policy-
relevant recommendations for the uptake of cost-
effectiveness evidence in prioritising decisions on essen-
tial chronic disease care packages in South Asia.
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